Kaken Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019; Provides Dividend Guidance for the Year Ending March 31, 2019
The company provided consolidated earnings guidance for the year ending March 31, 2019. For the period, the company expects net sales to be of JPY 94,800 million, operating profit expects of JPY 22,500 million, profit attributable to owners of parent of JPY 16,400 million and basic earnings per share of JPY 412.91.
The company provided dividend guidance for the year ending March 31, 2019. For the period, the company expects to pay dividend of JPY 75.00 per share compared to JPY 75.00 per share paid a year ago.